Arrhythmias & electrophysiology
Ablation for Atrial Fibrillation in Patients With Rare Pathogenic Variants in Cardiomyopathy and Arrhythmia Genes
Main finding · AF recurrenceResult — go to the resultHazard ratio 1.15 95% CI 0.84–1.60Authors' conclusion
Our results support the use of AF ablation for most patients with rare pathogenic CM or arrhythmia variants, including TTN. However, patients with ALVC variants, such as LMNA, may be at a significantly higher risk for arrhythmia recurrence.
Study context
- Population
- Patients undergoing atrial fibrillation (AF) catheter ablation with whole exome sequencing
- Participants
- 1,366 patients
- Exposure
- P/LP variant in cardiomyopathy (CM) or arrhythmia gene vs no P/LP variant
- P/LP variantn = 109
- Outcome
- ≥30 seconds of any atrial tachyarrhythmia after a 90-day blanking period
Methodological detailsobservational
- Observational
Main finding
AF recurrence
Hazard ratio
1.15
95% CI 0.84–1.60
P = 0.53
P/LP variantvs Genotype-negative
HR 1.15 (95% CI 0.84–1.60); P = 0.53
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | HR (95% CI) | P value | |
|---|---|---|---|
| Recurrence, ALVC gene group (predominantly LMNA)ALVCvs ARVC, DCM, HCM and channelopathy gene groupsn = 10 | 3.75 (1.84–7.63) | P < 0.001 | |
| Recurrence, P/LP TTN variantsTTNvs Genotype-negativen = 46 | 0.93 (0.54–1.59) | P = 0.78 | |
| 0.10.31310Hazard ratio (log scale) |
Original publication
Ablation for Atrial Fibrillation in Patients With Rare Pathogenic Variants in Cardiomyopathy and Arrhythmia Genes. JACC Clin Electrophysiol. Published 4 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →